Anti-HLA-G Alexa Fluor® 488

Anti-HLA-G Alexa Fluor<sup>®</sup> 488
Regulatory status
RUO
Antigen
HLA-G
Clone
87G
Format
Alexa Fluor® 488
Reactivity
Human
Excitation laser
blue (488 nm)
Variant
0.1 mg
A4-437-C100
In stock
340.00 USD

0.025 mg
A4-437-C025
Delivery 1 week
170.00 USD
Variant
0.1 mg
11-261-C100
In stock
340.00 USD

0.1 mg
11-261-C100
In stock
170.00 USD
Product details
Description
References
Isotype
Mouse IgG2a
Specificity
The antibody 87G recognizes both membrane-bound and soluble forms of HLA-G (HLA-G1 and HLA-G5). HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells. The antibody 87G blocks interaction of HLA-G with inhibitory receptors.
Application details
Flow cytometry: Extracellular and intracellular staining; recommended dilution: 1-3 μg/ml; positive control: JEG-3 human choriocarcinoma epithelial cell line.
Reactivity
Human
Negative species
Mouse, Rat
Immunogen
HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and expressing genes encoding HLA-G and human beta2-microglobulin.
Concentration
1 mg/ml
Preparation
Purified antibody is conjugated with Alexa Fluor® 488 NHS ester under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Licence note
Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.
Licence label
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.
Antigen description
Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
Entrez Gene ID 3135
UniProt ID P17693

General references:

Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003 39(4):587-94.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, LeDanff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 64(3):315-26.
PubMed
Lin A, Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 2018 Sep 27;9:2164.
PubMed
Hunt JS, Langat DK, McIntire RH, Morales PJ: The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4 Suppl 1(Suppl 1):S10.
PubMed
Xu HH, Yan WH, Lin A: The role of HLA-G in human papillomavirus infections and cervical carcinogenesis. Front Immunol. 2020 Jun 25;11:1349.
PubMed
Castelli EC, de Almeida BS, Muniz YC, Silva NS, Passos MR, Souza AS, Page AE, Dyble M, Smith D, Aguileta G, Bertranpetit J, Migliano AB, Duarte YA, Scliar MO, Wang J, Passos-Bueno MR, Naslavsky MS, Zatz M, Mendes CT, Donadi EA: HLA-G genetic diversity and evolutive aspects in worldwide populations. Sci Rep. 2021 Nov 29;11(1):23070.
PubMed
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A: Molecular pathways: Human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013 Oct 15;19(20):5564-71.
PubMed

Product specific references:

Sageshima N, Ishitani A, Omura M, Akasaki M, Umekage H, Katabuchi H, Okamura H, Hatake K: Necrotic feature of the trophoblasts lacking HLA-G expression in normal and pre-eclamptic placentas. Am J Reprod Immunol. 2003 Mar;49(3):174-82.
PubMed
Riteau B. et al.: HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 13(2), 193 (2001).
PubMed
Ishitani A. et al.: Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F and G in Maternal-Placental Immune Recognitions. The Journal of Immunology 171, 1376 (2003).
PubMed
Polakova K, Bandzuchova E, Hofmeister V, Weiss EH, Hutter H, Russ G: Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. Neoplasma. 2003;50(5):331-8.
PubMed
Polakova K, Krcova M, Kuba D, Russ G: Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res. 2003 Jul;27(7):643-8.
PubMed
Hackmon R, Hallak M, Krup M, Weitzman D, Sheiner E, Kaplan B, Weinstein Y: HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy. Fetal Diagn Ther. 2004 Sep-Oct;19(5):404-9.
PubMed
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED: HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005 Nov 15;65(22):10139-44.
PubMed
Shobu T, Sageshima N, Tokui H, Omura M, Saito K, Nagatsuka Y, Nakanishi M, Hayashi Y, Hatake K, Ishitani A: The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation. J Reprod Immunol. 2006 Dec;72(1-2):18-32.
PubMed
LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED: Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007 Mar 1;109(5):2040-8.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 Mar;64(3):315-26.
PubMed
Wiendl H: The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain. 126(Pt 1), 176 (2003).
PubMed
Variant
0.1 mg
A4-437-C100
In stock
340.00 USD

0.025 mg
A4-437-C025
Delivery 1 week
170.00 USD
Variant
0.1 mg
11-261-C100
In stock
340.00 USD

0.1 mg
11-261-C100
In stock
170.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
200.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
60.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
50.00 USD
-134%
ClonePPV-04
Reg. statusRUO
0.1 mg
210.00 USD
-134%
CloneMOPC-173
Reg. statusRUO
0.1 mg
210.00 USD